세계의 수막염균 백신 시장(2025-2032년)

The global meningococcal vaccine market reached US$ 3.5 billion in 2023 and is expected to reach US$ 6.1 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

A meningococcal vaccine is a biological preparation designed to protect individuals against infections caused by Neisseria meningitidis, a bacterium responsible for meningococcal disease. Meningococcal disease can manifest as meningitis (inflammation of the membranes surrounding the brain and spinal cord) or septicemia (bloodstream infection), both of which are life-threatening conditions. Meningococcal vaccine induces immunity by stimulating the body's production of antibodies specific to Neisseria meningitidis. The vaccine offers protection against invasive diseases such as bacterial meningitis and septicemia.

The global meningococcal vaccine market is experiencing significant growth, driven by increasing awareness of meningococcal disease, government immunization initiatives and advancements in vaccine technology. For instance, according to ScienceDirect, between 2017 and 2021 a total number of 48,617 individuals were vaccinated against meningococcal disease within the health policy programs implemented by Local Government Units (LGUs) in Poland, which accounted for approximately 10 % of all vaccinated against meningococcal disease in Poland.

Market Dynamics: Drivers & Restraints

Rising incidence of meningococcal disease

The rising incidence of meningococcal disease is significantly driving the growth of the meningococcal vaccine market and is expected to drive the market over the forecast period due to increased awareness, proactive vaccination campaigns and higher public health priority. The rising incidence of meningococcal disease increases the demand for meningococcal vaccines to slow the severity of the condition.

For instance, according to the National Centre for Disease Control, the incidence of meningococcal meningitis during the last 30 years varies from 1-3/100,000 in most developed countries to 10-25/100,000 in developing countries. Globally, nearly half a million cases of meningococcal disease occur each year accounting for 50,000 deaths.

Additionally, according to the Centers for Disease Control and Prevention (CDC), U.S. cases of meningococcal disease have increased sharply since 2021 and now exceed pre-pandemic levels. In 2023, 438 confirmed and probable cases were reported. Moreover, according to the Institut Pasteur, in 2023 in France, 560 cases of meningococcal meningitis and 59 deaths were recorded. In the first quarter of 2024, 180 people were affected.

Advancements in vaccine technology have made it easier to develop effective vaccines against multiple serogroups. The introduction of multivalent vaccines, which can protect against several serogroups simultaneously, has expanded the scope of vaccination programs and increased market penetration.

For instance, in October 2023, Pfizer Inc. cleared the U.S. Food and Drug Administration (FDA) approval of PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA combines the components from two meningococcal vaccines, Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine) to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.

High vaccine costs

High vaccine costs are expected to hamper the growth of the meningococcal vaccine market by limiting access, particularly in low- and middle-income countries and affecting vaccine uptake among certain populations. The high cost of the vaccine makes it unaffordable for many individuals, especially in regions where healthcare budgets are limited and where infectious diseases compete for funding with other health priorities.

The higher cost of multivalent vaccines (covering multiple serogroups) reduces their adoption compared to monovalent vaccines. The affordability challenge affects public health budgets, leading to prioritization of single-serogroup vaccines over more comprehensive ones. High vaccine costs can lead to low uptake rates, particularly among vulnerable populations and in regions with limited public health infrastructure. The economic burden is a significant deterrent, especially when individuals face other urgent needs or competing healthcare priorities.

Segment Analysis

The global meningococcal vaccine market is segmented based on type, product type, end-user and region.

Product Type:

The conjugate meningococcal vaccines segment is expected to dominate the meningococcal vaccine market share

Conjugate vaccines are more effective in stimulating an immune response, particularly in young children and infants. This segment includes vaccines like MenACWY (covering A, C, W, and Y serogroups) and MenB (covering serogroup B). There is an increasing demand for conjugate meningococcal vaccines, thus it's a dominating segment in the market. For instance, according to the study conducted by ScienceDirect, in total, 14,832,054 meningococcal C conjugate vaccine doses were administered throughout the study investigated period.

Conjugate vaccines provide broader serogroup coverage, which is crucial for controlling outbreaks in high-risk populations. These vaccines have been developed to cover multiple serogroups (A, C, W, Y), making them more versatile compared to other vaccine types that cover fewer serogroups.

For instance, the introduction of MenACWY vaccines in Africa, such as the MenAfriVac, has significantly reduced the incidence of serogroup A meningococcal disease. MenAfriVac, developed by the Serum Institute of India and supported by Gavi, targets serogroup A and has been widely distributed across the African meningitis belt (Gavi).

Geographical Analysis

North America is expected to hold a significant position in the meningococcal vaccine market share

Major pharmaceutical companies, including GSK, Pfizer, and Sanofi, are heavily investing in North America due to the region's large market size and demand for high-quality vaccines. This has led to the availability of advanced conjugate vaccines, like MenACWY and MenB, which are specifically targeted to control outbreaks in the region.

For instance, in November 2024, GSK plc announced that the European Commission (EC) approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.

Additionally, in October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA combines the components from two meningococcal vaccines, Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine) to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.

North America has a well-established healthcare infrastructure, which allows for efficient distribution and administration of vaccines. The region's healthcare system enables comprehensive vaccination campaigns and the use of advanced technologies to track immunization records.

For instance, in the United States, the Vaccines for Children program ensures that vaccines are widely distributed, tracked, and administered. The ability to integrate vaccine information into health records facilitates high vaccination coverage and real-time monitoring. In Canada, the Immunization Monitoring Program (IMPACT) helps track vaccine distribution and coverage rates, which supports the widespread use of meningococcal vaccines across the country

Asia-Pacific is growing at the fastest pace in the meningococcal vaccine market

The role of organizations like Gavi has been crucial in facilitating access to affordable vaccines in the Asia Pacific. Gavi's support has helped countries in the region secure vaccines through pooled procurement programs, thus reducing costs and improving availability. For instance, Gavi has supported large-scale vaccination campaigns in Southeast Asia to control outbreaks, such as the one seen in Papua New Guinea in 2021. The partnership has enabled the introduction of MenAfriVac and other vaccines, contributing to better coverage and control of the disease.

Major players like GSK, Pfizer, and Sanofi are focusing on the Asia Pacific market, driven by the rapid growth potential. These companies are expanding their product portfolios and increasing production capacity to meet the rising demand. For instance, GSK's MenACWY vaccine has been widely adopted across Asia Pacific countries, driven by its effectiveness and integration into public health programs. Pfizer's MenB vaccines, such as Bexsero, are also gaining traction in the region due to increasing awareness and vaccination campaigns targeting university students and military personnel

Competitive Landscape

The major global players in the meningococcal vaccine market include Sanofi S.A., GlaxoSmithKline Inc., Merck & Co., Inc., Pfizer Inc., Bio-Med (P) Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Meningococcal Vaccine market report delivers a detailed analysis with 56 key tables, more than 51 visually impactful figures, and 149 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Type
• 2.4. Snippet by Product Type
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising incidence of meningococcal disease
  • 3.1.2. Restraints
    • 3.1.2.1. High vaccine costs
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. Latin America
  • 4.6.5. Middle East & Africa
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Meningococcal Vaccine Market, By Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 5.1.2. Market Attractiveness Index, By Type
• 5.2. Monovalent*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Quadrivalent
• 5.4. Bivalent
• 5.5. Others

6. Meningococcal Vaccine Market, By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Polysaccharide Meningococcal Vaccines*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Conjugate Meningococcal Vaccines
• 6.4. Serogroup Meningococcal Vaccines

7. Meningococcal Vaccine Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Public Health Agencies
• 7.5. Others

8. Meningococcal Vaccine Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Sanofi S.A.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. GlaxoSmithKline Inc.
• 10.3. Merck & Co., Inc.
• 10.4. Pfizer Inc.
• 10.5. Bio-Med (P) Limited
• 10.6. Serum Institute of India Pvt. Ltd.
• 10.7. Walvax Biotechnology Co., Ltd.
• 10.8. Incepta Pharmaceuticals Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us